| Date Filed | Type | Description |
| 10/10/2023 |
SC 13G/A
| STATE STREET CORP reports a 2.3% stake in EXIT FILING FATE THERAPEUTICS INC |
| 08/18/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/08/2023 |
8-K
| Quarterly results |
| 08/04/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 07/05/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 07/05/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/09/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 06/08/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 06/07/2023 |
8-K
| Other Events Interactive Data |
| 05/10/2023 |
SC 13G/A
| STATE STREET CORP reports a 14.2% stake in AMENDED FILING FATE THERAPEUTICS INC |
| 04/21/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/21/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/21/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/19/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 04/19/2023 |
8-K
| Quarterly results |
| 04/18/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 04/14/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 03/22/2023 |
SC 13G
| MILLENNIUM MANAGEMENT LLC reports a 1.7% stake in FATE THERAPEUTICS, INC. |
| 03/10/2023 |
SC 13G/A
| VANGUARD GROUP INC reports a 10.1% stake in Fate Therapeutics Inc. |
| 02/28/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/28/2023 |
8-K
| Quarterly results |
| 02/09/2023 |
SC 13G/A
| VANGUARD GROUP INC reports a 8.2% stake in Fate Therapeutics Inc. |
| 02/03/2023 |
SC 13G
| STATE STREET CORP reports a 6.1% stake in INITIAL FILING FATE THERAPEUTICS INC |
| 01/06/2023 |
SC 13G/A
| BlackRock Inc. reports a 10% stake in FATE THERAPEUTICS INC |
| 01/05/2023 |
8-K
| Termination of a Material Definitive Agreement, Cost Associated with Exit or Disposal Activities, Departure of Directors or C... |
| 11/07/2022 |
8-K
| Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits Inte...|
Docs:
|
"ONO PHARMACEUTICAL CO., LTD. 8-2, Kyutaromachi 1-Chome, Chuo-ku, Osaka-shi 541-8564, JAPAN TEL : 81-6-6263-5670 FAX : 81-6-6263-2976 November 7, 2022 Fate Therapeutics, Inc. Corporate Headquarters 12278 Scripps Summit Drive San Diego, CA 92131 United States of America Attention: Mr. Scott Wolchko Re: Amendment to Collaboration and Option Agreement with respect to Collaboration Candidate 2 Dear Mr. Scott Wolchko: Reference is made to Collaboration and Option Agreement dated September 14, 2018 entered into by FATE Therapeutics, Inc. and Ono Pharmaceutical Co., Ltd. , as amended to date. Unless otherwise expressly defined in this letter agreement , the defined terms used or referenced herein have the meaning ascribed to such terms in the Agreement. The Amendment shall be effective on November...",
"Fate Therapeutics Announces Exercise by ONO Pharmaceutical of Option to HER2-targeted CAR T-Cell Product Candidate for Solid Tumors Multiplexed-engineered, iPSC-derived CAR T-cell Product Candidate Demonstrated Broad, Potent and Specific CAR Activity Across Multiple Preclinical Solid Tumor Models Fate and ONO to Jointly Develop and Commercialize FT825/ONO-8250 in U.S. and Europe with ONO having Exclusive Rights in Rest of World San Diego, CA – November 7, 2022 – Fate Therapeutics, Inc. , a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that ONO Pharmaceutical Co., Ltd. has exercised its option to FT825/ONO-8250, a multiplexed-engineered, iPSC-derived, chimeric antigen receptor T-cell pro..." |
|
| 11/03/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/03/2022 |
8-K
| Quarterly results |
| 08/03/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/03/2022 |
8-K
| Quarterly results |
| 06/30/2022 |
8-K
| Quarterly results |
| 06/13/2022 |
8-K
| Quarterly results |
| 06/09/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
|